New: Biosimilars strategies introduced.
Close
Valuable and timely information on drug therapy issues impacting today's health care and pharmacy environment.
April 15, 2019 - The FDA announced the discontinuation of Ironwood Pharmaceuticals’ Duzallo (lesinurad/allopurinol) and Zurampic (lesinurad).
Download PDF
Return to publications
